Home
Portfolio
News
Contact
ArriVent Receives FDA Breakthrough Therapy Designation for Furmonertinib for First-Line Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Arrivent Biopharma
related
news
ADARx Pharmaceuticals raises 4.463 million in upsized US IPO
Reuters
September 25 2026
NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy
NASDAQ
July 14 2026
Get In Touch
Contact Us